Recombinant human erythropoietin administration in cardiac surgery


Creative Commons License

Yazicioglu L., Eryilmaz S., Sirlak M., Inan M., Aral A., Tasoz R., ...Daha Fazla

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, cilt.122, sa.4, ss.741-745, 2001 (SCI-Expanded, Scopus) identifier identifier identifier

Özet

Objective: Postoperative anemia and multiple blood transfusions are still important problems in cardiac surgery. During the past few years, there have been some reports indicating that multiple recombinant human erythropoietin infusions starting at least 2 weeks before the operation induced erythropoiesis. We aimed to reduce the risk of adverse reactions of high doses of recombinant human erythropoietin and reduce the period of hospitalization by using it only once, 4 days before the operation.